Ester Fernandez-Salas
Overview
Explore the profile of Ester Fernandez-Salas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, et al.
Neoplasia
. 2024 Oct;
57():101064.
PMID: 39389678
No abstract available.
2.
Anderson A, Parashar K, Jin K, Clor J, Stagnaro C, Vani U, et al.
Mol Cancer Ther
. 2024 May;
23(10):1471-1482.
PMID: 38797955
AB598 is a CD39 inhibitory antibody being pursued for the treatment of solid tumors in combination with chemotherapy and immunotherapy. CD39 metabolizes extracellular adenosine triphosphate (eATP), an alarmin capable of...
3.
Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, et al.
Neoplasia
. 2024 Mar;
51:100986.
PMID: 38492449
No abstract available.
4.
Zheng C, Rej R, Wang M, Huang L, Fernandez-Salas E, Yang C, et al.
ACS Med Chem Lett
. 2023 Oct;
14(10):1389-1395.
PMID: 37849536
Lysine specific demethylase 1 (LSD1) acts as an epigenetic eraser by specifically demethylating mono- and histone 3 lysine 4 (H3K4) and H3 lysine 9 (H3K9) residues. LSD1 has been pursued...
5.
Qiao Y, Choi J, Tien J, Simko S, Rajendiran T, Vo J, et al.
Nat Cancer
. 2021 Nov;
2:978-993.
PMID: 34738088
Multi-tyrosine kinase inhibitors (MTKIs) have thus far had limited success in the treatment of castration-resistant prostate cancer (CRPC). Here, we report a phase I-cleared orally bioavailable MTKI, ESK981, with a...
6.
Rej R, Wang C, Lu J, Wang M, Petrunak E, Zawacki K, et al.
J Med Chem
. 2020 Jun;
63(13):7252-7267.
PMID: 32580550
Inhibition of embryonic ectoderm development (EED) is a new cancer therapeutic strategy. Herein, we report our discovery of EEDi-5285 as an exceptionally potent, efficacious, and orally active EED inhibitor. EEDi-5285...
7.
Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, et al.
Neoplasia
. 2020 Jan;
22(2):111-119.
PMID: 31931431
Androgen receptor (AR) antagonists, such as enzalutamide, have had a major impact on the treatment of metastatic castration-resistant prostate cancer (CRPC). However, even with the advent of AR antagonist therapies,...
8.
Aguilar A, Zheng K, Xu T, Xu S, Huang L, Fernandez-Salas E, et al.
J Med Chem
. 2019 Jun;
62(13):6015-6034.
PMID: 31244110
Inhibition of the menin-mixed lineage leukemia (MLL) protein-protein interaction is a promising new therapeutic strategy for the treatment of acute leukemia carrying MLL fusion (MLL leukemia). We describe herein our...
9.
Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang C, et al.
J Med Chem
. 2019 Jan;
62(2):941-964.
PMID: 30629437
We report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by compound 34 (ARD-69). ARD-69 induces degradation of AR protein in AR-positive prostate cancer...
10.
Qin C, Hu Y, Zhou B, Fernandez-Salas E, Yang C, Liu L, et al.
J Med Chem
. 2018 Jul;
61(15):6685-6704.
PMID: 30019901
Proteins of the bromodomain and extra-terminal (BET) family are epigenetics "readers" and promising therapeutic targets for cancer and other human diseases. We describe herein a structure-guided design of [1,4]oxazepines as...